Skip to main content

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Completed · Phase 3 · NCT04336722

Conditions: Biliary Atresia

At a glance

Research payments reported, 2025
$504,808
U.S. investigators named
25
Sites paid
26
Planned or actual enrollment
254

About the trial

Sponsor
Albireo, an Ipsen Company
Tested
Odevixibat (drug), Placebo (drug)
Dates
Started 2020-07-08; completion 2026-06-22
Results posted
Not yet

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Albireo Pharma, Inc. reported $504,808 in research payments for this study in 2025 (166 payments).

Products named: Bylvay

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.